---
title: Clinical efficiency and patient safety of INTERCEPT Blood System
description: Effectiveness of conventional vs INTERCEPT treated platelets before and after implementation of PI
image: https://insights.interceptbloodsystem.com/hubfs/New%20publication%20confirms%20that%20the%20INTERCEPT%E2%84%A2%20Blood%20System%20for%20platelets%20did%20not%20adversely%20affect%20clinical%20outcomes%20for%20massively%20transfused%20patients.jpg
---

This site provides INTERCEPT product information for International audiences [Select your region](https://interceptbloodsystem.com/en)

- [English](https://insights.interceptbloodsystem.com)
- [Deutsch](https://insights.interceptbloodsystem.com/de)

[![INTERCEPT Blood System™](https://insights.interceptbloodsystem.com/hs-fs/hubfs/Logo/logo-cerus.png?width=148&height=58&name=logo-cerus.png "INTERCEPT Blood System™")](http://interceptbloodsystem.com/)

- [About](http://interceptbloodsystem.com/about)
- [Insights](https://insights.interceptbloodsystem.com/)
- [Cerus Campus](https://info.interceptbloodsystem.com/cerus_campus)
- [Resources](http://interceptbloodsystem.com/resources)
- [Contact](http://interceptbloodsystem.com/en/contact)
- [Ask an expert](http://interceptbloodsystem.com/en/ask-expert)

- [Blood center](https://interceptbloodsystem.com/en/blood-center)
- [Healthcare professional](https://interceptbloodsystem.com/en/healthcare-professional)
- [General blood safety](https://interceptbloodsystem.com/en/general-blood-safety)

[![Cerus logo](https://insights.interceptbloodsystem.com/hs-fs/hubfs/Logo/logo-cerus-footer.png?width=121&height=30&name=logo-cerus-footer.png "Cerus logo")](http://interceptbloodsystem.com/) 

Menu

# Insights

[Home](https://interceptbloodsystem.com/) » [Insights](https://insights.interceptbloodsystem.com) » Clinical efficiency and patient safety of INTERCEPT Blood System

### Categories

- [Cerus (17)](https://insights.interceptbloodsystem.com/topic/cerus)
- [Economics (1)](https://insights.interceptbloodsystem.com/topic/economics)
- [Guidelines (1)](https://insights.interceptbloodsystem.com/topic/guidelines)
- [Hospital News (2)](https://insights.interceptbloodsystem.com/topic/hospital-news)
- [Regulations (1)](https://insights.interceptbloodsystem.com/topic/regulations)
- [Transfusion-Transmitted Infections (8)](https://insights.interceptbloodsystem.com/topic/transfusion-transmitted-infections)

[![sub newsletter](https://insights.interceptbloodsystem.com/hs-fs/hubfs/sub%20newsletter.jpg?width=250&height=63&name=sub%20newsletter.jpg)](https://interceptbloodsystem.com/en/newsletter)

# Clinical efficiency and patient safety of INTERCEPT Blood System

06/08/2018

- [Hospital News](https://insights.interceptbloodsystem.com/topic/hospital-news)

![New publication confirms that the INTERCEPT™ Blood System for platelets did not adversely affect clinical outcomes for massively transfused patients](https://insights.interceptbloodsystem.com/hs-fs/hubfs/New%20publication%20confirms%20that%20the%20INTERCEPT%E2%84%A2%20Blood%20System%20for%20platelets%20did%20not%20adversely%20affect%20clinical%20outcomes%20for%20massively%20transfused%20patients.jpg?width=1200&name=New%20publication%20confirms%20that%20the%20INTERCEPT%E2%84%A2%20Blood%20System%20for%20platelets%20did%20not%20adversely%20affect%20clinical%20outcomes%20for%20massively%20transfused%20patients.jpg)

The INTERCEPTTM Blood System for platelets has demonstrated clinical efficacy for treating and preventing bleeding in clinical trials and in routine use.[1](http://interceptbloodsystem.com/en/insight/new-publication-confirms-intercepttm-blood-system-platelets-did-not-adversely-affect#Source)

While many studies were performed in haematology/oncology patients, this study focused on the clinical efficacy during massive transfusion.

The retrospective cohort analysis concluded that the introduction of INTERCEPT-treated platelet concentrates did not adversely affect clinical outcomes in massively transfused patients in terms of blood product usage, in-hospital mortality and length of stay for a range of clinical indications for platelet transfusion support.

Results of the study were recently published in Vox Sanguinis - The Internal Journal of Transfusion Medicine.

[Access the abstract and open access article.](http://onlinelibrary.wiley.com/doi/10.1111/vox.12489/abstract?campaign=wolearlyview)

 

Nussbaumer, W., Amato, M., Schennach, H., Astl, M., Chen, C. Y., Lin, J.-S., Corash, L. and Benjamin, R. J. (2017), Patient outcomes and amotosalen/UVA-treated platelet utilization in massively transfused patients. Vox Sang, 112: 249–256. doi:10.1111/vox.12489

[← The economics of Double Dose Buffy Coat Platelets](https://insights.interceptbloodsystem.com/the-economics-of-double-dose-buffy-coat-platelets)

[Let us do something about it! →](https://insights.interceptbloodsystem.com/let-us-do-something-about-it)

Share this article

[![Share on Facebook](https://static.hubspot.com/final/img/common/icons/social/facebook-24x24.png)](http://www.facebook.com/share.php?u=https%3A%2F%2Finsights.interceptbloodsystem.com%2Fclinical-efficiency-and-patient-safety-of-intercept-blood-system%3Futm_medium%3Dsocial%26utm_source%3Dfacebook) [![Share on LinkedIn](https://static.hubspot.com/final/img/common/icons/social/linkedin-24x24.png)](http://www.linkedin.com/shareArticle?mini=true&url=https%3A%2F%2Finsights.interceptbloodsystem.com%2Fclinical-efficiency-and-patient-safety-of-intercept-blood-system%3Futm_medium%3Dsocial%26utm_source%3Dlinkedin) [![Share on Twitter](https://static.hubspot.com/final/img/common/icons/social/twitter-24x24.png)](https://twitter.com/intent/tweet?original_referer=https%3A%2F%2Finsights.interceptbloodsystem.com%2Fclinical-efficiency-and-patient-safety-of-intercept-blood-system%3Futm_medium%3Dsocial%26utm_source%3Dtwitter&url=https%3A%2F%2Finsights.interceptbloodsystem.com%2Fclinical-efficiency-and-patient-safety-of-intercept-blood-system%3Futm_medium%3Dsocial%26utm_source%3Dtwitter&source=tweetbutton&text=Clinical%20efficiency%20and%20patient%20safety%20of%20INTERCEPT%20Blood%20System) [![Share on Email](https://static.hubspot.com/final/img/common/icons/social/email-24x24.png)](mailto:?subject=Check%20out%20https%3A%2F%2Finsights.interceptbloodsystem.com%2Fclinical-efficiency-and-patient-safety-of-intercept-blood-system%3Futm_medium%3Dsocial%26utm_source%3Demail%20&body=Check%20out%20https%3A%2F%2Finsights.interceptbloodsystem.com%2Fclinical-efficiency-and-patient-safety-of-intercept-blood-system%3Futm_medium%3Dsocial%26utm_source%3Demail)

### Newsletter

Want to stay updated on the latest pathogen inactivation news?  
You can receive our highlights by subscribing to our newsletter.

[Subscribe to our newsletter](https://info.interceptbloodsystem.com/en/newsletter)

### Ask an Expert

Do you have questions about the INTERCEPT™ Blood System, blood safety or blood transfusions? The INTERCEPT team has plenty of knowledge and expertise.

[Ask an Expert](http://interceptbloodsystem.com/ask-expert)

[![Cerus logo](https://insights.interceptbloodsystem.com/hs-fs/hubfs/Logo/logo-cerus-footer.png?width=121&height=30&name=logo-cerus-footer.png "Cerus logo")](http://interceptbloodsystem.com/)

- [Legal Info](http://interceptbloodsystem.com/legal-info)
- [Privacy Policy](http://interceptbloodsystem.com/privacy-policy)
- [Cookies](http://interceptbloodsystem.com/cookies)

The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located.  
Use of INTERCEPT Plasma or Platelets is contraindicated in patients with a history or allergic response to amotosalen or psoralens. Consult instructions for use for indications, contraindications, warnings, and precautions.

Cerus, INTERCEPT and the Cerus logo are trademarks of Cerus Corporation.

© 2023 Cerus Corporation. All Rights Reserved. MKT-EN 00157 v43.0